DINESH

Jupiter Life Line Hospitals

Industry: Healthcare
Latest CMP 316
Today's Change ▼ -0.08%
52-Week High / Low 332 | 240
Price Date: 14-Aug-2026
Recommendation Sell
Target Price 338
Expected Upside 3.4%
Forecast Horizon 2 Years
Historical CAGR Not Available
1,000 Invested
Today's Value
Investment Period < 5 Years

Stock Snapshot

Post Results Return
+3.7%
Mild Positive Re-rating
1-Year Target Price
286
2-Year Target Price
338
52-Week High / Low
332 / 240
20-Day Return
+1.3%
Market Cap (Cr.)
10,350
Current PE
51.6
P/BV Ratio
1.3
Dividend Yield
0.1%
Industry PE
57.2

Price Performance

Basis of our Recommendation

Jupiter Life Line Hospitals (JLHL) is navigating a critical phase of expansion, with management emphasizing a strategic increase in bed capacity to approximately 3,000 beds over the next few years. This growth is underpinned by the development of new facilities in high-density urban markets, which is expected to enhance revenue streams and improve average revenue per occupied bed (ARPOB) by around 10% year-over-year. However, execution risks remain, particularly with the Dombivli unit currently operating at a loss and facing challenges in occupancy and insurance empanelments. Vista's financial outlook reflects these dynamics, projecting moderate revenue growth amid margin pressures due to initial ramp-up costs and operational inefficiencies. The healthcare sector's stable pricing power and ongoing demand for organized care provide a supportive backdrop, although margin pressures from rising operational costs and regulatory risks are notable headwinds. Over the next 12-24 months, key opportunities include successful execution of expansion plans and operational efficiencies, while watchpoints include the performance of new facilities and potential regulatory changes that could impact profitability

👍 Why We Like This Stock

  • Strategic expansion plans to increase bed capacity to ~3,000 beds, enhancing revenue potential
  • Projected ~10% YoY growth in ARPOB driven by improved case-mix and payer contract repricing
  • Stable pricing power in the healthcare sector supports long-term revenue growth

Things To Watch Out For

  • Execution risks associated with the Dombivli unit, currently operating at a loss with low occupancy
  • Margin pressures from higher operational costs and initial ramp-up losses in new facilities
  • Potential regulatory changes and labor costs could impact operational efficiency and profitability

Key Parameters

Balance Sheet Strength
Conservatively Financed
Market Share
Stable
Industry Outlook
Stable
Analyst View
Strong Buy
Dividend History
Consistent
FII Holdings
Increasing

Financial Snapshot

Actuals Forecast
FY24 FY25 FY26 FY27 FY28
Revenue (Cr.) 1,073 1,262 1,500 1,584 1,846
Profit Before Tax (Cr.) 195 252 265 214 273
PBT Margin 18.2% 19.9% 1766.7% 13.5% 14.8%
Net Profit (Cr.) 177 189 200 162 207
Earnings Per Share 5.4 5.8 6.1 4.9 6.3

Analyst Recommendations

Broker Recommendation Target Price Date
Anand Rathi ▲ Buy 312 19-May-2026
Choice Equity ▲ Buy 329 03-Jun-2026
ICICI Securities ▲ Buy 320 19-May-2026
Prabhudas Liladhar ▲ Buy 360 04-Aug-2026
Consensus Recommendation ▲ Strong Buy
Consensus Target 344
Coverage 4 Analysts
Analysts' Viewpoint
Jupiter Life Line Hospitals' strategic expansion in Western India, including the addition of 1,500 beds across four new hospitals, is expected to drive sustainable growth. The acquisition of an IV fluids manufacturing entity is anticipated to enhance procurement efficiencies and margins. However, execution risks at the Dombivli unit, currently operating at a loss, and increased costs in Indore due to pre-expansion activities pose challenges. Key future catalysts include the phased rollout of the Dombivli facility and the commissioning of the Pune South hospital by CY28.

Company Overview

Show Company Profile

Jupiter Life Line Hospitals Limited, a multi-specialty hospital, provides health care services under the Jupiter brand in India. The company offers treatments in the areas of bariatric surgery, breast care center, cardiac surgery, cardiology, chest medicine, dental care, dermatology, endocrinology and diabetes, ENT, gastroenterology, general surgery and minimal access surgery, hematology and BMT, HPB and surgical gastroenterology, infectious diseases, internal medicine, interventional radiology, mental health, nephrology, neurology, neurosurgery, nutrition and dietetics, Obs and gynecology, oncology, ophthalmology, organ transplant, orthopedics, pediatrics, pain clinic, plastic and cosmetic surgery, rehabilitation, rheumatology, robotic knee replacement, robotic surgery, TAVI/TAVR, and urology. It also operates hotel under the Fortune Park Lake City Hotel brand in Thane. The company was incorporated in 2002 and is based in Mumbai, India.